Gilead Sciences (GILD) Revenue (2009 - 2026)

Gilead Sciences has reported Revenue for 18 years, with the latest figure at $7.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 4.39% year-over-year to $7.0 billion; the trailing twelve-month figure through Mar 2026 stood at $29.7 billion (up 3.48% YoY), and the FY2025 full-year result was $29.4 billion, up 2.4% from the prior year.
• Revenue for Q1 2026 stood at $7.0 billion, down from $7.9 billion in the prior quarter.
• The five-year high for Revenue was $7.9 billion in Q4 2025, with the low at $6.3 billion in Q2 2022.
• Historically, Revenue has averaged $7.0 billion across 5 years, with a median of $7.0 billion in 2022.
• Annual changes were most pronounced in 2022 — Revenue decreased 5.11% — and 2024, when it advanced 7.01%.
• Gilead Sciences' Revenue stood at $7.4 billion in 2022, then fell by 3.72% to $7.1 billion in 2023, then grew by 6.4% to $7.6 billion in 2024, then climbed by 4.7% to $7.9 billion in 2025, then slipped by 12.18% to $7.0 billion in 2026.
• The last three Revenue figures came in at $7.0 billion (Q1 2026), $7.9 billion (Q4 2025), and $7.8 billion (Q3 2025), per Business Quant data.